Concerns about the latest NICE draft guidance on statins

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  McPherson, Klim ^a  

^a NEW COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG SAFETY; FUNDING; HORMONE SUBSTITUTION; HUMAN; LETTER; NATIONAL HEALTH ORGANIZATION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC;

EID: 84904045099     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g4130     Document Type: Letter

References (6)

1. Godlee F. Adverse effects of statins. BMJ 2014;348:g3306. (15 May.)
2. McPherson K. One expert's experience. In: Experts in civil courts, Expert Witness Institute. Blom-Cooper L, ed. Oxford University Press, 2006.
3. McPherson K, Hemminki E. Synthesising licensing data to assess drug safety. BMJ 2004;328:518-20. (Pubitemid 38293623)
4. Abbasi K. The missing data that cost £20bn. BMJ 2014;348:g2695.
5. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816
6. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.